List of Excipients in Branded Drug EPIVIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	EPIVIR	lamivudine	0173-0662	CELLULOSE, MICROCRYSTALLINE
GlaxoSmithKline LLC	EPIVIR	lamivudine	0173-0662	FERRIC OXIDE RED
GlaxoSmithKline LLC	EPIVIR	lamivudine	0173-0662	FERRIC OXIDE YELLOW
GlaxoSmithKline LLC	EPIVIR	lamivudine	0173-0662	HYPROMELLOSE
GlaxoSmithKline LLC	EPIVIR	lamivudine	0173-0662	MAGNESIUM STEARATE

Epivir Excipient Strategy and Commercial Opportunities for Lamivudine

Last updated: August 30, 2026

Epivir is a mature lamivudine product with limited originator exclusivity and substantial generic competition. The commercial opportunity is not a new-composition patent position. It is in low-cost excipient supply, pediatric taste masking, oral-liquid stability, fixed-dose combination manufacturing, regulatory support, and differentiated medicines for HIV and hepatitis B markets.

What is Epivir and how is it formulated?

Epivir contains lamivudine, a nucleoside reverse transcriptase inhibitor used with other antiretrovirals for HIV-1 infection. The product is also marketed as Epivir-HBV at a lower dose for chronic hepatitis B. GlaxoSmithKline developed Epivir; ViiV Healthcare manages the HIV portfolio following the formation of ViiV as a GSK-Pfizer joint venture.[1][2]

The U.S. Epivir dosage forms are:

Product	Strength	Dosage form	Primary commercial use
Epivir	150 mg	Tablet	HIV treatment
Epivir	300 mg	Tablet	HIV treatment
Epivir	10 mg/mL	Oral solution	Pediatric and adult HIV treatment

The U.S. label identifies the tablets as containing lamivudine with conventional excipients including microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hypromellose, titanium dioxide and polyethylene glycol. The oral solution uses a sucrose-containing aqueous system with buffering agents, preservatives and flavoring components.[1]

The excipient system is conventional rather than technically differentiated. Its value lies in reproducible manufacturability, acceptable dissolution, oral-liquid stability and patient acceptability.

What excipients are used in Epivir tablets?

Epivir tablets use a standard direct-compression or high-shear granulation-compatible platform. The principal excipient functions are:

Excipient class	Representative Epivir component	Function
Diluent and compression aid	Microcrystalline cellulose	Tablet mass, compactability and mechanical strength
Disintegrant	Sodium starch glycolate	Rapid tablet breakup and dissolution
Lubricant	Magnesium stearate	Ejection and manufacturing control
Film former	Hypromellose	Protective coating and swallowability
Opacifier and colorant	Titanium dioxide	Tablet appearance and opacity
Plasticizer or coating aid	Polyethylene glycol	Film flexibility and coating performance

The tablet strategy is commercially important because lamivudine is a high-volume generic active pharmaceutical ingredient. Manufacturers generally seek an excipient system that supports low-cost production, stable dissolution across equipment platforms and simple regulatory justification.

What are the key tablet excipient risks?

The principal technical risks are not novel formulation risks. They are manufacturing and quality risks:

1. Excessive magnesium stearate can reduce wettability and slow dissolution.
2. Sodium starch glycolate performance can vary with grade, substitution level and moisture.
3. Microcrystalline cellulose can affect tablet hardness, friability and disintegration.
4. Coating systems can alter appearance, weight gain and swallowability.
5. Supplier changes can trigger comparative dissolution, stability and post-approval change work.

For generic manufacturers, dual sourcing of microcrystalline cellulose, sodium starch glycolate, magnesium stearate and coating polymers can reduce supply interruption risk. The highest-value suppliers are those that provide consistent particle-size distribution, low bioburden, strong documentation and change-control support.

What excipients are used in Epivir oral solution?

The oral solution creates more commercial complexity than the tablet because lamivudine must remain chemically and microbiologically stable in an aqueous, multidose package.

The labeled formulation includes:

• Sucrose as a sweetening and bulking agent
• Sodium citrate and citric acid as buffering components
• Methylparaben and propylparaben as preservatives
• Artificial strawberry flavor
• Purified water as the vehicle

The exact commercial formulation should be verified against the current approved labeling and market-specific dossier before use in a regulatory filing.[1]

Why is pediatric taste masking a commercial opportunity?

Lamivudine oral solution is relevant to infants and children who cannot reliably swallow tablets. Taste is a major adherence variable in chronic pediatric HIV therapy. A supplier or contract development organization can create value through:

• Improved flavor systems with lower bitterness
• Reduced aftertaste
• Lower sucrose formulations
• Sugar-free systems using alternative sweeteners
• Preservative-reduced or preservative-free presentations
• Smaller-volume dosing
• Oral syringes with dose markings and child-resistant packaging

Any reformulation must preserve assay, impurities, microbiological quality, preservative effectiveness, viscosity, dose uniformity, stability and compatibility with the dosing device.

A lower-sugar or sugar-free product could be commercially relevant in pediatric and public-health settings. The opportunity is strongest where caregivers administer repeated daily doses and where dental health, diabetes risk or storage conditions affect product selection.

What excipient strategies can differentiate generic lamivudine?

Generic lamivudine is difficult to differentiate through the active ingredient because the molecule, dosage strengths and clinical use are established. Differentiation must come from administration, manufacturing economics or market access.

1. Taste-masked oral solution

A taste-masked product could target pediatric HIV programs and private-market caregivers. Ion-exchange resins, cyclodextrins, polymeric taste blockers and optimized flavor systems are possible development routes. The formulation must avoid compromising lamivudine release or creating sedimentation and dose-uniformity problems.

2. Sugar-free oral liquid

A sugar-free product could use polyols or high-intensity sweeteners. The formulation must address viscosity, osmolarity, laxation risk, preservative performance and palatability. A sugar-free label claim may improve positioning in some private markets but will not by itself create strong patent exclusivity.

3. Ready-to-use dispersible tablets

Dispersible or rapidly dispersing tablets could expand use among children and patients with swallowing difficulty. Commercial value depends on whether the product offers a meaningful advantage over existing oral solution and whether it reduces shipping and storage costs.

4. Low-water-activity or dry formulations

Powders for reconstitution can reduce water-related degradation and shipping weight. The tradeoff is the need for caregiver reconstitution, dose measurement and post-reconstitution stability. These products may be useful in markets with weak cold-chain or pharmacy infrastructure, although lamivudine itself generally does not require refrigerated distribution.

5. Excipient localization

Regional sourcing of pharmaceutical-grade excipients can reduce foreign-exchange exposure, freight cost and procurement risk. Localized supply is most valuable for high-volume public tenders, where a small per-unit cost reduction can materially affect margins.

What patents protect Epivir and its excipient system?

The original lamivudine compound and antiviral patent estate is mature. The key early U.S. lamivudine patent was U.S. Patent No. 5,047,407, which covered nucleoside analog compounds including lamivudine-related subject matter. Its term expired before the current generic market matured.[3]

The commercial formulation does not appear to have a strong, current U.S. exclusivity position based on the conventional tablet and oral-solution excipient systems described in the approved labeling. Any patent analysis must distinguish:

• Lamivudine compound patents
• Salt, crystal-form or stereochemical patents
• Tablet formulation patents
• Oral-solution stability or taste-masking patents
• Combination-product patents
• Method-of-use patents
• Manufacturing-process patents

A new excipient system could support patent claims if it produces a non-obvious technical result, such as improved stability, reduced degradation, superior palatability, controlled release or a specific preservative-free shelf life. Merely replacing one conventional filler, lubricant or sweetener with another is unlikely to create a durable blocking position.

When does Epivir lose exclusivity?

Epivir lost practical market exclusivity years ago. The FDA approved Epivir tablets and oral solution in 1995.[1] The five-year new chemical entity exclusivity period for the original lamivudine product has expired, and generic lamivudine products are established in the United States and international markets.

Exclusivity category	Epivir position
FDA approval	1995
Five-year NCE exclusivity	Expired
Pediatric exclusivity	Any historical extension is expired
Orphan exclusivity	Not applicable to the core product
Biosimilar exclusivity	Not applicable
Current practical market protection	None comparable to a launch-stage branded product

Epivir-HBV is a separate lower-dose branding strategy, not a biologic or protected reference product with biosimilar exposure. Lamivudine is a small molecule regulated through the generic drug pathway.

What is the Orange Book status of Epivir?

The FDA Orange Book is the relevant source for listed patents, exclusivity and therapeutic-equivalence information for approved small-molecule products.[4] Epivir’s historical Orange Book significance relates to its original approved products and any listed patents that supported the reference product during the generic-approval period.

A current diligence review should distinguish between:

• Active reference listings
• Expired patents
• Delisted patents
• Product-specific patents
• Paragraph IV certifications filed against any still-listed patents

Because the core Epivir patent estate is old, the principal regulatory issue for a new generic is usually abbreviated new drug application approval, bioequivalence, formulation control and manufacturing compliance rather than an active originator patent barrier.

Which companies are challenging Epivir through generic competition?

Lamivudine is supplied by multiple generic manufacturers globally. Market participants have included large multinational generic companies, regional manufacturers and suppliers serving antiretroviral procurement programs. The competitive field includes manufacturers of:

• Lamivudine tablets
• Lamivudine oral solution
• Lamivudine-zidovudine combinations
• Lamivudine-tenofovir combinations
• Other fixed-dose antiretroviral products

A complete current company-by-company list requires a live review of FDA product approvals, WHO prequalification records, national registers and tender awards. The commercial conclusion is clear: generic entry is established, and the main competitive variables are price, quality, supply continuity and public-procurement eligibility.

What generic entry risks exist for Epivir?

Generic entry risk is high because:

• The active ingredient is well characterized.
• The product has long clinical use.
• The main dosage forms are conventional.
• The compound patent estate is expired.
• No biosimilar development pathway is relevant.
• Multiple alternative antiretroviral regimens exist.
• Buyers in public-health markets are price sensitive.

The remaining barriers are operational. They include API qualification, dissolution performance, oral-liquid microbiological control, stability data, supplier qualification, packaging compatibility and inspection readiness.

For oral solution, the regulatory burden can exceed the apparent formulation simplicity. Preservative effectiveness, microbial limits, in-use stability and dosing-device performance can determine approval timing and post-market quality.

What formulation and method-of-use patents could create new value?

New intellectual-property opportunities would need to focus on a specific technical or clinical advantage. Candidate areas include:

Opportunity	Potential claim focus	Commercial strength
Pediatric taste masking	Defined polymer, resin or flavor system	Moderate if palatability data are strong
Sugar-free oral liquid	Composition with stability and preservative performance	Moderate
Dispersible tablet	Rapid dispersion and dose uniformity	Moderate
Long-acting delivery	Injectable or implantable lamivudine system	High technical risk
Fixed-dose combination	Specific ratios and stability profile	Depends on combination
Low-cost manufacturing	Process with measurable yield or impurity benefit	Usually limited blocking value
New method of use	Narrow patient population or regimen	Limited if clinically redundant

Method-of-use patents face a high invalidity and non-infringement risk when the claimed use overlaps established lamivudine treatment. Combination products may offer more practical value when they address adherence, pediatric dosing or simplified treatment.

How does Epivir compare with competing lamivudine products?

Attribute	Epivir	Generic lamivudine	Fixed-dose combination
Active ingredient	Lamivudine	Lamivudine	Lamivudine plus another antiretroviral
Brand protection	Historical	None as a brand category	Product-specific
Main advantage	Established reference product	Lower price	Fewer tablets and simplified dosing
Excipient opportunity	Reformulation or lifecycle management	Cost and performance optimization	Stability and compatibility across APIs
Main risk	Continued substitution	Price competition	Combination-specific regulatory complexity
Commercial growth	Limited for mature branded product	Tender and emerging-market volume	Adherence and regimen simplification

In many treatment settings, lamivudine competes indirectly with newer nucleoside and nucleotide products. A differentiated lamivudine formulation must therefore solve a specific administration, adherence or access problem.

What is the revenue exposure for Epivir?

ViiV and GSK do not generally present Epivir as a major standalone growth product in public corporate reporting. Revenue exposure is likely concentrated in legacy HIV sales, selected international markets, combination products and supply arrangements rather than a high-margin U.S. branded franchise.[2]

The largest commercial opportunity is for suppliers and manufacturers, not for a conventional branded relaunch. Relevant opportunities include:

1. High-volume generic tablet production.
2. Pediatric oral-solution supply.
3. Public-health tenders in low- and middle-income countries.
4. Contract manufacturing for regional pharmaceutical companies.
5. Improved dosing devices and packaging.
6. Excipient supply agreements with documented regulatory support.
7. Fixed-dose combination development.

What manufacturing and geographic barriers affect commercial entry?

The United States and European markets require validated manufacturing, bioequivalence and current good manufacturing practice compliance. Emerging markets may offer larger volume opportunities but impose country-specific registration, local representation, pharmacovigilance and procurement requirements.

Geographic opportunity is strongest where HIV treatment programs continue to use lamivudine-based regimens and where procurement agencies value reliable supply. The primary barriers are:

• API and excipient supply continuity
• Quality-system maturity
• Stability under climatic Zone IV conditions
• Packaging suitable for heat and humidity
• Public-tender price pressure
• Local registration timelines
• Product serialization and traceability
• Pediatric formulation access

A supplier with a qualified, change-controlled excipient platform can win business even when the excipient itself is commoditized. Documentation, consistency and audit performance often matter more than formulation novelty.

Key Takeaways

• Epivir contains lamivudine and is available primarily as 150 mg and 300 mg tablets plus a 10 mg/mL oral solution.
• The tablet excipient system is conventional and offers limited standalone patent value.
• The oral solution provides the strongest formulation opportunity because taste, sugar content, preservative systems and dosing-device compatibility affect pediatric use.
• Epivir’s original exclusivity and core compound patent protection have expired.
• Lamivudine is a small molecule, so biosimilar risk does not apply.
• Generic entry risk is high, while manufacturing, quality and procurement execution remain the principal barriers.
• The most attractive commercial opportunities are pediatric formulations, sugar-free or taste-masked liquids, dispersible tablets, excipient localization and fixed-dose combinations.
• Epivir is a mature product with limited standalone branded revenue growth potential.

FAQs

Can a new excipient combination obtain patents for lamivudine?

Yes, but the formulation must provide a non-obvious technical result. Improved stability, taste masking, preservative performance or dispersibility is more defensible than routine substitution of one conventional excipient for another.

Is lamivudine oral solution more commercially attractive than lamivudine tablets?

It can be. Oral solution has greater formulation complexity and more room for differentiation, particularly in pediatric taste masking, sugar reduction, dosing accuracy and in-use stability.

Does Epivir have biosimilar competition?

No. Lamivudine is a chemically synthesized small molecule. Competing products are generics approved through small-molecule pathways, not biosimilars.

Could a sugar-free Epivir formulation command premium pricing?

A sugar-free formulation could support differentiated positioning, but premium pricing would depend on documented clinical or adherence value, market access and procurement conditions. Sugar reduction alone is unlikely to create durable market exclusivity.

What is the strongest geographic opportunity for lamivudine excipients?

The strongest opportunities are high-volume HIV treatment markets and public-health procurement channels where reliable supply, climatic stability, low unit cost and regulatory documentation determine supplier selection.

References

1. U.S. Food and Drug Administration. (n.d.). Epivir (lamivudine) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

2. ViiV Healthcare. (2024). Annual and corporate reporting materials. https://www.viivhealthcare.com/

3. U.S. Patent and Trademark Office. (1991). U.S. Patent No. 5,047,407: Nucleoside analogues. https://patents.google.com/patent/US5047407

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files/